Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 31st total of 8,400 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days.

Daxor Price Performance

Shares of Daxor stock traded up $0.03 during trading on Tuesday, hitting $7.81. 557 shares of the stock traded hands, compared to its average volume of 5,255. Daxor has a 52 week low of $7.19 and a 52 week high of $10.00. The firm’s fifty day moving average is $8.33 and its 200-day moving average is $8.73.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its holdings in shares of Daxor Co. (NASDAQ:DXR) by 34.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.